Lewes, DE -- (SBWIRE) -- 03/25/2014 -- The present Competitive Intelligence report about Cancer Vaccines provides a competitor evaluation in the field of novel prophylactic and therapeutic vaccines to fight cancer as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Projects are listed according to their main antigenic constituents: peptides, recombinant proteins, idiotype antibody, DNA (plasmid, expression vector), RNA, virus-like particles (VLP), dendritic cells, tumor cells (tumor cell lines), microorganism-based and others.
Of the 140 clinical stage cancer vaccines, three were approved and are commercialized in the major pharmaceutical markets with combined 2013 sales of US$ 2,385 mln. Peptides and proteins make out 43% of clinical stage cancer vaccines, followed by dendritic cell and tumor cell (line)-based cancer vaccines with each contributing 15% to the clinical cancer vaccine pipeline. DNA- and RNA-based cancer vaccines maked out 17% of the clinical portfolio.
The report includes a compilation of currently active projects in research and development for prophylaxis and therapy of cancer. In addition, the report lists company-specific R&D pipelines of cancer vaccines. Competitor projects are listed in a tabular format providing information on:
- Drug Codes
- Target / Mechanism of Action
- Class of Compound
- Product Category
- R&D Stage and
About Competitor Analysis Series
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Spanning Over 179 pages , “Competitor Analysis- Cancer Vaccines” report covering the Cancer Vaccines by Main Composition (Peptide-based Cancer Vaccines, Protein-based Cancer Vaccines, Idiotype Antibody-based Cancer Vaccines, DNA-based Cancer Vaccines: naked and virally vectored, RNA-based Cancer Vaccines, Virus-Like Particle (VLP)-based Cancer Vaccines, Dendritic Cell-based Cancer Vaccines, Tumor Cell and Tumor Cell Line – based Cancer Vaccines, Microorganism-based Cancer Vaccines, Other and Not Defined Cancer Vaccines), Corporate Cancer Vaccines R&D Pipelines. The report covered companies Partial List - ABIVAX, Activartis, Aduro BioTech, Advanced Cancer Therapeutics, Advaxis, Aeterna Zentaris, Agenus, Antigen Express, ApoVax, Ascend Biopharmaceuticals, Asterias Biotherapeutics, Avax Technologies, Bavarian Nordic.
Know more about this report at: http://www.marketresearchreports.com/la-merie-publishing/competitor-analysis-cancer-vaccines
Find other Biotechnology Reports at : http://www.marketresearchreports.com/biotechnology
About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.
For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter
For Pharma Reports: http://www.linkedin.com/company/pharmaceuticals